Transcatheter mitral valve replacement (TMVR) is a novel therapeutic option for patients with severe mitral regurgitation (MR) at high or prohibitive surgical risk. Most TMVR technologies under investigation use either a trans-apical or a trans-septal approach via dedicated multistep anchoring systems. Transcatheter mitral valve replacement offers several potential advantages over transcatheter repair, notably a greater and more sustained MR reduction. At the same time, significant engineering challenges and potential disadvantages must be acknowledged. Preclinical and clinical studies have shown promising results, demonstrating TMVR feasibility. Nevertheless, further development, testing, and trials are needed before considering TMVR as a definitive therapeutic option for MR in a wide range of anatomical scenarios.
Reference: Transcatheter mitral valve replacement: there is still work to be done. Bartorelli AL, Monizzi G, Mastrangelo A, Grancini L, Fabbiocchi F, Conte E, Moltrasio M, Andreini D.
Eur Heart J Suppl. 2022 Nov 12;24(Suppl I):I16-I21.